Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 68, Issue 8, 2013, Pages 994-1000

  Gaffal, E ^a   Cron, M ^a   Glodde, N ^a   Tuting T ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

cannabinoids; contact allergy; inflammation; keratinocytes; T cells

Indexed keywords

1 FLUORO 2,4 DINITROBENZENE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DRONABINOL; GAMMA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN ALLERGY; T LYMPHOCYTE; WILD TYPE;

CANNABINOIDS; CONTACT ALLERGY; INFLAMMATION; KERATINOCYTES; T CELLS;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DERMATITIS, ALLERGIC CONTACT; DINITROFLUOROBENZENE; DISEASE MODELS, ANIMAL; DRONABINOL; INTERFERON-GAMMA; KERATINOCYTES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PRIMARY CELL CULTURE; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 84883149080     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12183     Document Type: Article

References (29)

1. Martin SF, Esser PR, Weber FC, Jakob T, Freudenberg MA, Schmidt M, et al. Mechanisms of chemical-induced innate immunity in allergic contact dermatitis. Allergy 2011; 66: 1152-1163.
2. Kaplan DH, Igyarto BZ, Gaspari AA,. Early immune events in the induction of allergic contact dermatitis. Nat Rev Immunol 2012; 12: 114-124.
3. Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S, et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 2007; 316: 1494-1497.
4. Petrosino S, Cristino L, Karsak M, Gaffal E, Ueda N, Tüting T, et al. Protective role of palmitoylethanolamide in contact allergic dermatitis. Allergy 2010; 65: 698-711.
5. Klein TW,. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005; 5: 400-411.
6. Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M,. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem 2009; 1: 1333-1349.
7. Kupczyk P, Reich A, Szepietowski JC,. Cannabinoid system in the skin-a possible target for future therapies in dermatology. Exp Dermatol 2009; 18: 669-679.
8. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC, et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 2000; 396: 141-149.
9. Oka S, Wakui J, Gokoh M, Kishimoto S, Sugiura T,. Suppression by WIN55212-2, a cannabinoid receptor agonist, of inflammatory reactions in mouse ear: Interference with the actions of an endogenous ligand, 2- arachidonoylglycerol. Eur J Pharmacol 2006; 538: 154-162.
10. Maccarrone M, Di RM, Battista N, Gasperi V, Guerrieri P, Rossi A, et al. The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J Biol Chem 2003; 278: 33896-33903.
11. Albanesi C,. Keratinocytes in allergic skin diseases. Curr Opin Allergy Clin Immunol 2010; 10: 452-456.
12. Braun A, Engel T, Aguilar-Pimentel JA, Zimmer A, Jakob T, Behrendt H, et al. Beneficial effects of cannabinoids (CB) in a murine model of allergen-induced airway inflammation: role of CB1/CB2 receptors. Immunobiology 2011; 216: 466-476.
13. Klein TW, Newton CA, Friedman H,. Cannabinoids and the immune system. Pain Res Manag 2001; 6: 95-101.
14. Klein TW, Newton CA, Widen R, Friedman H,. The effect of delta-9-tetrahydrocannabinol and 11-hydroxy-delta-9-tetrahydrocannabinol on T-lymphocyte and B-lymphocyte mitogen responses. J Immunopharmacol 1985; 7: 451-466.
15. Klein TW, Lane B, Newton CA, Friedman H,. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 2000; 225: 1-8.
16. Puffenbarger RA, Boothe AC, Cabral GA,. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 2000; 29: 58-69.
17. Leonti M, Casu L, Raduner S, Cottiglia F, Floris C, Altmann KH, et al. Falcarinol is a covalent cannabinoid CB1 receptor antagonist and induces pro-allergic effects in skin. Biochem Pharmacol 2010; 79: 1815-1826.
18. Wilkinson JD, Williamson EM,. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. J Dermatol Sci 2007; 45: 87-92.
19. Bloom AS, Edgemond WS, Moldvan JC,. Nonclassical and endogenous cannabinoids: effects on the ordering of brain membranes. Neurochem Res 1997; 22: 563-568.
20. Zhu W, Friedman H, Klein TW,. Delta9-tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of Bcl-2 and caspase-1. J Pharmacol Exp Ther 1998; 286: 1103-1109.
21. Derocq JM, Segui M, Marchand J, Le FG, Casellas P,. Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett 1995; 369: 177-182.
22. Denda M, Tsutsumi M,. Roles of transient receptor potential proteins (TRPs) in epidermal keratinocytes. Adv Exp Med Biol 2011; 704: 847-860.
23. Jordt SE, Bautista DM, Chuang HH, McKemy DD, Zygmunt PM, Hogestatt ED, et al. Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 2004; 427: 260-265.
24. Atoyan R, Shander D, Botchkareva NV,. Non-neuronal expression of transient receptor potential type A1 (TRPA1) in human skin. J Invest Dermatol 2009; 129: 2312-2315.
25. Perez-Gomez E, Andradas C, Flores JM, Quintanilla M, Paramio JM, Guzman M, et al. The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. Oncogene 2012; 10. [Epub ahead of print.]
26. Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Mo FM, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106: 133-145.
27. Ross RA,. The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 2009; 30: 156-163.
28. O'Sullivan SE, Kendall DA,. Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology 2010; 215: 611-616.
29. Stander S, Reinhardt HW, Luger TA,. Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus. Hautarzt 2006; 57: 801-807.